COVID‐19 leads to mortality of several patients and the cytokine storm is reportedly critical
in the patients. To reduce the cytokine storm, we would like to propose the interleukin (IL) 6 …

Cytokine storm syndrome (CSS) is a severe complication of inflammatory immune diseases
or treatment of malignancies; it may also appear during the progression of COVID-19. CSS …

Abstract Coronavirus Disease 2019 (COVID-19) continues to spread rapidly. Monoclonal
antibodies as well as anti-tumor necrosis factor are considered promising treatments for …

To recognize the period of exaggerated cytokine response in patients with coronavirus
disease 2019 (COVID‐19) pneumonia, and to describe the clinical outcomes of using …

Presently, we need more therapeutic molecules for this COVID-19 outbreak. The severity
and mortality of the disease is associated with a high level of release of cytokine in the …

Data suggest that interleukin (IL)-6 blockade could reduce mortality in severe COVID-19, yet
IL-6 is only modestly elevated in most patients. Chen et al. describe the role of soluble …

Cytokine release syndrome (CRS) may be the key factor in the pathology of severe
coronavirus disease 2019 (COVID-19). As a major driver in triggering CRS in patients with …

Abstract Coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory
syndrome coronavirus-2 (SARS-CoV-2) has posed a significant threat to global health. This …

Background Current evidence suggests an important role of the interleukin‐6 (IL‐6) pathway
in severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2)‐related cytokine …

Since December 2019, a viral pneumonia, named coronavirus disease 2019 (COVID-19),
from Wuhan, China, has swept the world. Although the case fatality rate is not high, the …